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Purpose
TNF inhibitors are established treatment for poly-juve-
nile idiopathic arthritis (pJIA), but there are needs of
alternative therapy for refractory patients. Tocilizumab
(TCZ) has been widely used for rheumatoid arthritis
(RA) in adults, and the effectiveness for systemic JIA
has been well-documented. However, the experience on
pJIA is limited. We compared the clinical courses of our
patients of RA and pJIA to estimate the effectiveness of
TCZ.
Methods
We retrospectively reviewed clinical finding and assessed
disease activity index-CRP (DAS-CRP) of four adults
with RA and one child with pJIA. Three of four RA are
pretreated patients by other biological agents (Inflixi-
mab, Adalimumab, Etanercept) and TCZ was first biolo-
gical agent for one RA and pJIA patients. All patients
had significant disease activity (High 4, Moderate 1)
when TCZ were administered.
Results
Three of four RA and a pJIA patients are met the remis-
sion criteria of DAS-CRP after 28 weeks administration
of TCZ. Another RA patient showed improvement
(DAS-CRP 5.19 ® 3.65). There was no apparent side
effect in any of the patient.
Conclusion
In this small series, TCZ provided benefit to all of five
patients (RA 4, pJIA 1). In the Post Marketing Surveil-
lance of pediatric case of TCZ (132 cases) in Japan,
TCZ showed high effectiveness (Remarkable effective
53.0%, Effective 42.4%) and safety in pJIA. TCZ may be
a good option to treat not only sJIA but also pJIA.
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